| Title |
Premature Menopause in Patients with BRCA1 Gene Mutation
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, June 2006
|
| DOI | 10.1007/s10549-006-9220-1 |
| Pubmed ID | |
| Authors |
Izabella Rzepka-Górska, Bogusław Tarnowski, Anita Chudecka-Głaz, Bohdan Górski, Dorota Zielińska, Aleksandra Tołoczko-Grabarek |
| Abstract |
This study was undertaken with regard to the gonadotropin theory of ovarian cancer advocated in the literature and was designed to disclose specific features of ovarian morphology in carriers of the BRCA1 gene mutation. We enrolled 171 patients and divided them into two groups: A (n=90)--operated for breast cancer (30 patients with and 60 without the BRCA1 mutation); B (n=81)--with the BRCA1 mutation qualified for preventive adnexectomy. According to the authors' classification described herein, some patients without the BRCA1 mutation retained "signs of estrogenization" in menopausal ovaries, revealing the role of estrogens as a factor promoting mammary carcinogenesis in these patients. A tendency to premature menopause was observed in BRCA1 mutation carriers of groups A and B as evidenced by the final menorrhea appearing at a younger age and almost total absence of "signs of estrogenization" in menopausal ovaries. It is concluded from these findings that earlier menopause in carriers of the BRCA1 mutation is associated with hypergonadotropic activity and may predispose to ovarian cancer at younger age. |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Unknown | 47 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 15% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Doctoral Student | 5 | 10% |
| Student > Master | 5 | 10% |
| Researcher | 3 | 6% |
| Other | 9 | 19% |
| Unknown | 14 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 35% |
| Agricultural and Biological Sciences | 7 | 15% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Nursing and Health Professions | 1 | 2% |
| Psychology | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 16 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2022.
All research outputs
#7,539,423
of 23,001,641 outputs
Outputs from Breast Cancer Research and Treatment
#1,673
of 4,677 outputs
Outputs of similar age
#22,813
of 64,826 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#17
of 31 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,677 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 64,826 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.